Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits

Type 2 diabetes mellitus (T2D) is one of the most serious global health problems. This is partly a result of its drastic increase in East Asia, which now comprises more than a quarter of the global diabetes population. Ethnicity and lifestyle factors are two determinants in the aetiology of T2D, and...

Full description

Bibliographic Details
Main Authors: Daisuke Yabe, Hitoshi Kuwata, Masahiro Iwasaki, Yutaka Seino
Format: Article
Language:English
Published: European Medical Journal 2015-11-01
Series:European Medical Journal Diabetes
Subjects:
Online Access:http://emjreviews.com/wp-content/uploads/Why-Are-Incretin-Based-Therapies-More-Efficient-in-East-Asians..-Perspectives-From-the-Pathophysiology-of-Type-2-Diabetes-and-East-Asian-Dietary-Habits.pdf
id doaj-343fcef49d0547c2a1886d16bf8cd1f8
record_format Article
spelling doaj-343fcef49d0547c2a1886d16bf8cd1f82020-11-24T23:46:09ZengEuropean Medical JournalEuropean Medical Journal Diabetes2054-61812015-11-01315765 Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary HabitsDaisuke Yabe0Hitoshi Kuwata1Masahiro Iwasaki2Yutaka Seino3Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan. Center for Metabolism and Clinical Nutrition, Kansai Electric Power Hospital, Osaka, Japan. Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan. Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, JapanCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, JapanCenter for Metabolism and Clinical Nutrition, Kansai Electric Power Hospital, Osaka, Japan. Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, JapanCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, JapanType 2 diabetes mellitus (T2D) is one of the most serious global health problems. This is partly a result of its drastic increase in East Asia, which now comprises more than a quarter of the global diabetes population. Ethnicity and lifestyle factors are two determinants in the aetiology of T2D, and changes such as increased animal fat intake and decreased physical activity link readily to T2D in East Asians, which is characterised primarily by β-cell dysfunction that is evident immediately after ingestion of glucose or a meal, and less adiposity compared with T2D in Caucasians. These pathophysiological differences have an important impact on therapeutic approaches. Incretin-based therapies, such as dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), have become widely available for the management of T2D. Incretins, glucose-dependent insulinotropic polypeptide, and glucagon-like peptide-1 are secreted from the gut in response to the ingestion of various nutrients, including carbohydrates, proteins, and fats, and enhance insulin secretion via a glucose-dependent pathway to exert their glucose-lowering effects. Recent meta-analyses of clinical trials of DPP-4i and GLP-1RA found the drugs to be more effective in East Asians, most likely due to amelioration of the primary β-cell dysfunction by increased stimulation through incretin activity. In addition, our finding that the glycosylated haemoglobin-lowering effects of DPP-4i are enhanced by fish intake, and possibly worsened by animal fat intake, suggests that dietary habits such as eating more fish and less meat can affect the secretion of incretins, and supports the greater efficacy of incretin-based therapies in East Asians.http://emjreviews.com/wp-content/uploads/Why-Are-Incretin-Based-Therapies-More-Efficient-in-East-Asians..-Perspectives-From-the-Pathophysiology-of-Type-2-Diabetes-and-East-Asian-Dietary-Habits.pdfdipeptidyl peptidase 4 (DPP-4) inhibitorEast Asianglucagon-like peptide-1 receptor agonist (GLP-1RA)incretinType 2 diabetes mellitus (T2D)
collection DOAJ
language English
format Article
sources DOAJ
author Daisuke Yabe
Hitoshi Kuwata
Masahiro Iwasaki
Yutaka Seino
spellingShingle Daisuke Yabe
Hitoshi Kuwata
Masahiro Iwasaki
Yutaka Seino
Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits
European Medical Journal Diabetes
dipeptidyl peptidase 4 (DPP-4) inhibitor
East Asian
glucagon-like peptide-1 receptor agonist (GLP-1RA)
incretin
Type 2 diabetes mellitus (T2D)
author_facet Daisuke Yabe
Hitoshi Kuwata
Masahiro Iwasaki
Yutaka Seino
author_sort Daisuke Yabe
title Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits
title_short Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits
title_full Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits
title_fullStr Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits
title_full_unstemmed Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits
title_sort why are incretin-based therapies more efficient in east asians? perspectives from the pathophysiology of type 2 diabetes and east asian dietary habits
publisher European Medical Journal
series European Medical Journal Diabetes
issn 2054-6181
publishDate 2015-11-01
description Type 2 diabetes mellitus (T2D) is one of the most serious global health problems. This is partly a result of its drastic increase in East Asia, which now comprises more than a quarter of the global diabetes population. Ethnicity and lifestyle factors are two determinants in the aetiology of T2D, and changes such as increased animal fat intake and decreased physical activity link readily to T2D in East Asians, which is characterised primarily by β-cell dysfunction that is evident immediately after ingestion of glucose or a meal, and less adiposity compared with T2D in Caucasians. These pathophysiological differences have an important impact on therapeutic approaches. Incretin-based therapies, such as dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), have become widely available for the management of T2D. Incretins, glucose-dependent insulinotropic polypeptide, and glucagon-like peptide-1 are secreted from the gut in response to the ingestion of various nutrients, including carbohydrates, proteins, and fats, and enhance insulin secretion via a glucose-dependent pathway to exert their glucose-lowering effects. Recent meta-analyses of clinical trials of DPP-4i and GLP-1RA found the drugs to be more effective in East Asians, most likely due to amelioration of the primary β-cell dysfunction by increased stimulation through incretin activity. In addition, our finding that the glycosylated haemoglobin-lowering effects of DPP-4i are enhanced by fish intake, and possibly worsened by animal fat intake, suggests that dietary habits such as eating more fish and less meat can affect the secretion of incretins, and supports the greater efficacy of incretin-based therapies in East Asians.
topic dipeptidyl peptidase 4 (DPP-4) inhibitor
East Asian
glucagon-like peptide-1 receptor agonist (GLP-1RA)
incretin
Type 2 diabetes mellitus (T2D)
url http://emjreviews.com/wp-content/uploads/Why-Are-Incretin-Based-Therapies-More-Efficient-in-East-Asians..-Perspectives-From-the-Pathophysiology-of-Type-2-Diabetes-and-East-Asian-Dietary-Habits.pdf
work_keys_str_mv AT daisukeyabe whyareincretinbasedtherapiesmoreefficientineastasiansperspectivesfromthepathophysiologyoftype2diabetesandeastasiandietaryhabits
AT hitoshikuwata whyareincretinbasedtherapiesmoreefficientineastasiansperspectivesfromthepathophysiologyoftype2diabetesandeastasiandietaryhabits
AT masahiroiwasaki whyareincretinbasedtherapiesmoreefficientineastasiansperspectivesfromthepathophysiologyoftype2diabetesandeastasiandietaryhabits
AT yutakaseino whyareincretinbasedtherapiesmoreefficientineastasiansperspectivesfromthepathophysiologyoftype2diabetesandeastasiandietaryhabits
_version_ 1725494356065910784